ETPrime

Suven Pharma - Cohance Lifesciences Share Price

  • 1,014.20-8.30 (-0.82%)
  • Volume: 1,07,808
  • Closed
  • Last Updated On: 03 Jun, 2025, 03:29 PM IST
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Suven Pharma - Cohance Lifesciences Share Price
  • 1,014.20-8.30 (-0.82%)
  • Volume: 1,07,808
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

STRONG BUY

Mean Recos by
6 Analysts

0

0

0

3

3

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Suven Pharma share price insights

View All

  • In the last 5 years, only 1.87 % trading sessions saw intraday declines higher than 5 % .

  • Company witnessed QoQ revenue growth of 27.79%, which is highest in the last 3 years. (Source: Consolidated Financials)

  • Daily MACD crossover appeared yesterday. Average price decline of -3.81% within 10 days of this signal in last 10 years.

  • Company has spent less than 1% of its operating revenues towards interest expenses and 12.93% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

  • Cohance Lifesciences Ltd. share price moved down by -0.82% from its previous close of Rs 1,022.50. Cohance Lifesciences Ltd. stock last traded price is 1,014.20

    Share PriceValue
    Today/Current/Last1,014.20
    Previous Day1,022.501,023.45

InsightsSuven Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		144.72
    EPS - TTM
    (₹)    		7.00
    MCap
    (₹ Cr.)    		39,079.23
    Sectoral MCap Rank
    		15
    PB Ratio
    (x)    		19.08
    Div Yield
    (%)    		0.00
    Face Value
    (₹)    		1.00
    Beta

    Beta

    1 Month-
    3 Months-
    6 Months-
    1 Year-
    3 Years-

    		-
    VWAP
    (₹)    		1,022.48
    52W H/L
    (₹)
    1,360.00 / 598.00

    Suven Pharma Share Price Returns

    1 Day-0.82%
    1 Week-7.14%
    1 Month-10.7%
    3 Months-11.04%
    1 Year66.13%
    3 Years106.33%
    5 Years501.9%

    ET Stock ScreenersTop Score Companies

    Check whether Suven Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Suven Pharma News & Analysis

    View all Suven Pharma Share News & Announcements

    Suven Pharma Share Recommendations

    Recent Recos

    STRONG BUY

    Current

    Mean Recos by 6 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹1400
    • OrganizationICICI Securities
    • BUY
    • Target₹602
    • OrganizationGeojit Financial Services
    • ACCUMULATE

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy3331
    Buy3331
    Hold----
    Sell----
    Strong Sell----
    # Analysts6662
    View all Stock Recommendations

    Suven Pharma Financials

    • Insights

      • Quarterly Topline Performance

        Company witnessed QoQ revenue growth of 27.79%, which is highest in the last 3 years. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 12.93% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
      Quarterly | AnnualMar 2025Dec 2024Sep 2024Jun 2024Mar 2024
      Total Income412.59322.86271.84248.85269.98
      Total Income Growth (%)27.7918.779.24-7.8315.30
      Total Expenses355.24209.80170.67164.16196.83
      Total Expenses Growth (%)69.3222.933.97-16.6017.56
      EBIT57.35113.06101.1784.6973.15
      EBIT Growth (%)-49.2711.7519.4615.779.61
      Profit after Tax (PAT)42.0182.8882.2160.7753.37
      PAT Growth (%)-49.310.8135.2813.8614.16
      EBIT Margin (%)13.9035.0237.2234.0327.09
      Net Profit Margin (%)10.1825.6730.2424.4219.77
      Basic EPS (₹)1.653.263.232.392.10
      Quarterly | AnnualMar 2025Dec 2024Sep 2024Jun 2024Mar 2024
      Total Income336.80290.57249.49240.04260.39
      Total Income Growth (%)15.9116.473.94-7.8114.81
      Total Expenses278.18173.37147.34151.04187.04
      Total Expenses Growth (%)60.4517.67-2.45-19.2519.88
      EBIT58.62117.20102.1589.0073.34
      EBIT Growth (%)-49.9814.7314.7821.353.64
      Profit after Tax (PAT)44.3486.3576.3365.0853.43
      PAT Growth (%)-48.6513.1317.2921.802.04
      EBIT Margin (%)17.4040.3340.9437.0828.17
      Net Profit Margin (%)13.1729.7230.5927.1120.52
      Basic EPS (₹)1.743.393.002.562.10
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue1,113.261,386.691,412.601,023.96851.91
      Total Revenue Growth (%)-19.72-1.8337.9620.20125.11
      Total Expenses707.59826.96786.12610.02495.61
      Total Expenses Growth (%)-14.445.1928.8723.08124.70
      Profit after Tax (PAT)300.28411.29453.80362.34317.00
      PAT Growth (%)-26.99-9.3725.2414.30190.10
      Operating Profit Margin (%)39.2942.1647.9241.9045.49
      Net Profit Margin (%)28.5630.6834.3735.8838.01
      Basic EPS (₹)11.8016.1617.8314.2324.91
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue1,080.091,374.631,508.011,023.96851.91
      Total Revenue Growth (%)-21.43-8.8447.2720.20125.11
      Total Expenses671.31795.24785.56609.98494.32
      Total Expenses Growth (%)-15.581.2328.7923.40124.11
      Profit after Tax (PAT)304.82432.60558.10308.65270.08
      PAT Growth (%)-29.54-22.4980.8214.28147.16
      Operating Profit Margin (%)40.6043.9655.1941.9045.50
      Net Profit Margin (%)29.7332.5242.2730.5632.39
      Basic EPS (₹)11.9716.9921.9212.1221.22

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets2,254.091,965.741,829.591,474.471,172.81
      Total Assets Growth (%)14.677.4424.0825.7249.78
      Total Liabilities203.42230.56302.41293.66328.05
      Total Liabilities Growth (%)-11.77-23.762.98-10.4870.21
      Total Equity2,050.661,735.181,527.181,180.81844.76
      Total Equity Growth (%)18.1813.6229.3339.7843.11
      Current Ratio (x)11.826.375.362.571.95
      Total Debt to Equity (x)0.020.040.060.120.22
      Contingent Liabilities56.3040.4329.3847.7078.83
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets2,240.721,958.331,804.891,358.831,110.88
      Total Assets Growth (%)14.428.5032.8322.3241.87
      Total Liabilities184.82208.95284.19293.64328.05
      Total Liabilities Growth (%)-11.55-26.48-3.22-10.4970.21
      Total Equity2,055.901,749.381,520.691,065.18782.83
      Total Equity Growth (%)17.5215.0442.7636.0732.62
      Current Ratio (x)11.476.195.312.571.95
      Total Debt to Equity (x)0.020.040.060.130.24
      Contingent Liabilities56.30190.8429.3847.7078.83

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Increase in Cash from Investing

        Company has used Rs 362.25 cr for investing activities which is an YoY increase of 85.92%. (Source: Consolidated Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities358.48450.91330.00383.44415.95
      Net Cash used in Investing Activities-362.25-194.84-136.21-311.40-421.53
      Net Cash flow from Financing Activities-13.80-235.83-156.41-76.556.37
      Net Cash Flow-17.5720.2437.38-4.510.79
      Closing Cash & Cash Equivalent47.2364.8044.567.1811.70
      Closing Cash & Cash Equivalent Growth (%)-27.1245.42520.48-38.597.27
      Total Debt/ CFO (x)0.110.160.290.370.45
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities370.65484.17269.89329.73367.78
      Net Cash used in Investing Activities-381.58-235.57-90.36-257.66-374.73
      Net Cash flow from Financing Activities-13.78-235.79-156.41-76.557.62
      Net Cash Flow-24.7112.8123.12-4.480.67
      Closing Cash & Cash Equivalent18.3143.0230.217.090.67
      Closing Cash & Cash Equivalent Growth (%)-57.4342.41325.85952.86-93.82
      Total Debt/ CFO (x)0.100.140.350.430.50

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)14.6423.7029.7130.6837.52
      Return on Capital Employed (%)19.2431.2739.0733.7139.01
      Return on Assets (%)13.3220.9224.8024.5727.02
      Interest Coverage Ratio (x)62.77112.74107.8249.7316.45
      Asset Turnover Ratio (x)0.500.710.810.8071.09
      Price to Earnings (x)57.4729.3334.7234.848.09
      Price to Book (x)8.406.9310.3010.683.04
      EV/EBITDA (x)36.8019.6423.4928.026.78
      EBITDA Margin (%)44.4845.7250.8845.0348.36
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)14.8224.7236.7028.9734.50
      Return on Capital Employed (%)19.4932.4145.6537.1441.66
      Return on Assets (%)13.6022.0930.9222.7124.31
      Interest Coverage Ratio (x)62.61116.41123.2249.7317.39
      Asset Turnover Ratio (x)0.490.710.830.8275.05
      Price to Earnings (x)56.8227.8628.2540.989.50
      Price to Book (x)8.386.8810.3411.843.28
      EV/EBITDA (x)37.0819.2120.5728.026.78
      EBITDA Margin (%)45.3647.1858.1545.0348.36

    Financial InsightsSuven Pharma

    • Income (P&L)
    • Cash Flow

      • Quarterly Topline Performance

        Company witnessed QoQ revenue growth of 27.79%, which is highest in the last 3 years. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 12.93% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 362.25 cr for investing activities which is an YoY increase of 85.92%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Suven Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Suven Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Suven Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Suven Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Suven Pharma Technicals

    • Bullish / Bearish signals for Suven Pharma basis selected technical indicators and moving average crossovers.

      MACD Crossover

      Bearish signal on daily chart

      Appeared on:

    Suven Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Suven Pharma 144.9718.9414.6419.2413.322.8039.2928.5611.8011.820.020.11
          Laurus Labs93.227.268.0112.083.834.3412.606.386.651.220.604.48
          Ajanta Pharma34.768.4424.2830.1018.3511.0026.0219.8073.562.850.000.00
          Piramal Pharma296.783.331.126.400.5810.648.340.190.691.540.585.29
          Gland Pharma37.682.887.6311.436.227.9419.6612.4342.404.330.030.29
          Add More
          Annual Ratios (%)

          Choose from Peers

          • J B Chemicals
          • Syngene Int.
          • Emcure Pharmaceuticals Ltd.
          • Wockhardt
          • Concord Biotech Ltd.

          Choose from Stocks

            See All Parameters

          Peers InsightsSuven Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Suven Pharma Shareholding Pattern

            • Loading...
              Showing Suven Pharma Shareholding as on Mar 2025
              CategoryMar 2025Dec 2024Sep 2024Jun 2024
              Promoters50.1050.1050.1050.10
              Pledge0.000.000.000.00
              FII11.0510.8410.709.79
              DII16.5916.6716.9517.41
              Mutual Funds13.0413.1514.1214.78
              Others22.2522.3922.2522.70
            • Showing Shareholding as on Mar 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters12,75,39,59250.10 %0.00
              Pledge00.00 %0.00
              FII2,81,28,46711.05 %0.21
              DII4,22,65,40516.59 %-0.07
              MF3,31,97,26913.04 %-0.11
              Others5,66,31,49222.25 %-0.13

            Suven Pharma MF Ownership

            MF Ownership details are not available.

            Top Searches:
            Suven Pharma News Suven Pharma Quarterly Results Suven Pharma Dividend Suven Pharma Q1 ResultsSuven Pharma Q2 ResultsSuven Pharma Q3 ResultsSuven Pharma Q4 Results

            Suven Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              May 28, 2025Mar 26, 2025Board MeetingAudited Results
              Feb 12, 2025Dec 27, 2024Board MeetingQuarterly Results
              Dec 19, 2024Nov 21, 2024POM-
              Nov 28, 2024Oct 28, 2024COM-
              Nov 12, 2024Sep 26, 2024Board MeetingQuarterly Results
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Special500%5.0Sep 09, 2022Aug 30, 2022
              Interim100%1.0Sep 09, 2022Aug 29, 2022
              Special100%1.0May 13, 2022May 03, 2022
              Interim100%1.0May 13, 2022May 02, 2022
              Special200%2.0Feb 15, 2022Feb 02, 2022
            • All TypesEx-DateRecord DateAnnounced onDetails
              BonusSep 25, 2020Sep 28, 2020Aug 17, 2020Bonus Ratio: 1 share(s) for every 1 shares held

            About Suven Pharma

            Cohance Lifesciences Ltd., incorporated in the year 2018, is a Small Cap company (having a market cap of Rs 39,117.49 Crore) operating in Pharmaceuticals sector. Cohance Lifesciences Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Duty Drawback and Other Operating Revenue for the year ending 31-Mar-2024. Show More

            • Executives

            • Auditors

            • AV

              Annaswamy Vaidheesh

              Executive Chairperson
              VP

              V Prasada Raju

              Managing Director
              SK

              Sudhir Kumar Singh

              Chief Executive Officer
              PP

              Pankaj Patwari

              Non Executive Director
              Show More
            • Karvy & Co.

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty 500, BSE 500, Nifty MNC, + 16 more

            Address

            215 Atrium, C Wing, 8th Floor,819-821, Andheri Kurla Road, Chakala,Andheri East, Chakala MIDC,Mumbai, Maharashtra - 400093

            Contact

            [email protected]

            www.suvenpharm.com

            More Details

            FAQs about Suven Pharma share

            • 1. What's Suven Pharma share price today and what are Suven Pharma share returns ?
              Suven Pharma share price is Rs 1,011.70 as on 03 Jun, 2025, 03:18 PM IST. Suven Pharma share price is down by 1.06% based on previous share price of Rs 1,058.2. Suven Pharma share price trend:
              • Last 1 Month: Suven Pharma share price moved down by 10.92%
              • Last 12 Months: Suven Pharma share price moved up 65.72%
            • 2. Which are the key peers to Suven Pharma ?
              Top 10 Peers for Suven Pharma are Syngene International Ltd., Piramal Pharma Ltd., Wockhardt Ltd., J B Chemicals & Pharmaceuticals Ltd., Ajanta Pharma Ltd., Laurus Labs Ltd., Gland Pharma Ltd., Concord Biotech Ltd., Emcure Pharmaceuticals Ltd. and Natco Pharma Ltd.
            • 3. What are the returns for Suven Pharma share?
              Return Performance of Suven Pharma Shares:
              • 1 Week: Suven Pharma share price moved down by 7.37%
              • 1 Month: Suven Pharma share price moved down by 10.92%
            • 4. What has been highest price of Suven Pharma share in last 52 weeks?
              52 Week high of Suven Pharma share is Rs 1,360.00 while 52 week low is Rs 598.00
            • 5. What's the market capitalization of Suven Pharma ?
              Within the Pharmaceuticals sector, Suven Pharma stock has a market cap rank of 15. Suven Pharma has a market cap of Rs 39,079.23 Cr.
            • 6. What are the key metrics to analyse Suven Pharma Share Price?
              Suven Pharma share can be quickly analyzed on following metrics:
              • Price to Book Ratio of 19.08
            • 7. What are the Suven Pharma quarterly results?
              On Consoldiated basis, Suven Pharma reported a total income and profit of Rs 412.59 Cr and Rs 42.01 respectively for quarter ending 2025-03-31. Total Income and profit for the year ending 2024-03-31 was Rs 1113.26 Cr and Rs 300.28 Cr.
            • 8. Is Suven Pharma giving dividend?
              An equity Special dividend of Rs 5 per share was declared by Suven Pharmaceuticals Ltd. on 30 Aug 2022. So, company has declared a dividend of 500% on face value of Rs 1 per share. The ex dividend date was 09 Sep 2022.
            • 9. Who's the owner of Suven Pharma ?
              Following are the key changes to Suven Pharma shareholding:
              • Promoter holding has not changed in last 9 months and holds 50.1 stake as on 31 Mar 2025
              • Domestic Institutional Investors holding have gone down from 17.41 (30 Jun 2024) to 16.59 (31 Mar 2025)
              • Foreign Institutional Investors holding has gone up from 9.79 (30 Jun 2024) to 11.05 (31 Mar 2025)
              • Other investor holding have gone down from 22.7 (30 Jun 2024) to 22.25 (31 Mar 2025)

            Trending in Markets

            Top Gainers As on 03:32 PM | 03 Jun 2025

            FACT1,046.80
            158.45 (17.84%)
            Brainbees Solutions371.95
            30.70 (9.00%)
            India Cements351.70
            22.20 (6.74%)
            Rashtriya Chemicals160.32
            10.00 (6.66%)
            Lloyds Metals1,442.10
            88.60 (6.55%)

            Top Losers As on 03:42 PM | 03 Jun 2025

            YES Bank20.86
            -2.43 (-10.40%)
            Aptus Value Housing307.00
            -29.50 (-8.77%)
            Ola Electric Mobilit49.33
            -4.36 (-8.11%)
            Reliance Power58.89
            -3.08 (-4.98%)
            Suzlon Energy68.15
            -3.04 (-4.28%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Suven Pharma Share Price
            The Economic Times
            BrowseCompanies:
            OSZAR »